Sheehan Jared, Ardizzone Caleb M, Khanna Mayank, Trauth Amber J, Hagensee Michael E, Ramsay Alistair J
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Department of Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Vaccines (Basel). 2023 Nov 15;11(11):1720. doi: 10.3390/vaccines11111720.
SARS-CoV-2 mRNA vaccines are administered as effective prophylactic measures for reducing virus transmission rates and disease severity. To enhance the durability of post-vaccination immunity and combat SARS-CoV-2 variants, boosters have been administered to two-dose vaccinees. However, long-term humoral responses following booster vaccination are not well characterized. A 16-member cohort of healthy SARS-CoV-2 naïve participants were enrolled in this study during a three-dose BNT162b2 vaccine series. Serum samples were collected from vaccinees over 420 days and screened for antigen (Ag)-specific antibody titers, IgG subclass distribution, and neutralizing antibody (nAb) responses. Vaccine boosting restored peak Ag-specific titers with sustained α-RBD IgG and IgA antibody responses when measured at six months post-boost. RBD- and spike-specific IgG4 antibody levels were markedly elevated in three-dose but not two-dose immune sera. Although strong neutralization responses were detected in two- and three-dose vaccine sera, these rapidly decayed to pre-immune levels by four and six months, respectively. While boosters enhanced serum IgG Ab reactivity and nAb responses against variant strains, all variants tested showed resistance to two- and three-dose immune sera. Our data reflect the poor durability of vaccine-induced nAb responses which are a strong predictor of protection from symptomatic SARS-CoV-2 infection. The induction of IgG4-switched humoral responses may permit extended viral persistence via the downregulation of Fc-mediated effector functions.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)信使核糖核酸(mRNA)疫苗作为降低病毒传播率和疾病严重程度的有效预防措施进行接种。为了提高疫苗接种后免疫的持久性并对抗SARS-CoV-2变体,已对接种两剂疫苗的人群进行了加强接种。然而,加强接种后的长期体液反应尚未得到充分表征。在一个三剂次BNT162b2疫苗接种系列期间,16名未感染过SARS-CoV-2的健康参与者被纳入本研究。在420多天的时间里从接种者中采集血清样本,并检测抗原(Ag)特异性抗体滴度、IgG亚类分布和中和抗体(nAb)反应。加强接种后六个月测量时,疫苗加强接种恢复了峰值Ag特异性滴度,并伴有持续的α-RBD IgG和IgA抗体反应。三剂次免疫血清中RBD和刺突特异性IgG4抗体水平显著升高,而两剂次免疫血清中则未升高。虽然在两剂次和三剂次疫苗血清中均检测到强烈的中和反应,但这些反应分别在四个月和六个月时迅速衰减至免疫前水平。虽然加强接种增强了血清IgG抗体反应性和针对变异株的nAb反应,但所有测试的变异株均对两剂次和三剂次免疫血清具有抗性。我们的数据反映了疫苗诱导的nAb反应的持久性较差,而nAb反应是预防有症状SARS-CoV-2感染的有力预测指标。IgG4转换的体液反应的诱导可能通过下调Fc介导的效应功能而允许病毒长期持续存在。